Risk factors associated with palbociclib-induced neutropenia in patients with metastatic breast cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
https://link.springer.com/content/pdf/10.1007/s00520-022-07400-z.pdf
Reference23 articles.
1. Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925–1936
2. Turner NC, Slamon DJ, Ro J et al (2018) Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 379(20):1926–1936
3. (2019) Ibrance (palbociclib) [prescribing information]. Pfizer Labs, New York
4. Laurenti E, Frelin C, Xie S et al (2015) CDK6 level regulate quiescence exit in human hematopoietic stem cells. Cell Stem Cell 16(3):302–313
5. Kish JK, Ward MA, Garofalo D et al (2018) Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval. Breast Cancer Res 20:37
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2- advanced breast cancer: a phase III RCTs based meta-analysis;BMC Cancer;2024-08-21
2. Genetic susceptibility to breast cancer increases the risk of neutropenia and agranulocytosis: insights from Mendelian randomization;Supportive Care in Cancer;2024-06-29
3. CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety;Seminars in Oncology;2023-12
4. Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure;Biomedicine & Pharmacotherapy;2023-08
5. Real-World Predictors of Severe Neutropenia Associated with Palbociclib and Endocrine Therapy for Metastatic Breast Cancer in Japanese Patients;Biological and Pharmaceutical Bulletin;2023-08-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3